Loma Therapeutics is a Danish biotech company in the pre-clinical stage, developing immunotherapies for HPV-driven diseases, including cancer and pre-cancer. Our platform targets four HPV antigens (E1, E2, E6, E7) to induce broader and more effective immune responses than approaches focused on E6/E7 alone. The lead program is in pre-clinical development, with plans to enter first-in-human trials in early 2028.